Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02369874 · ClinicalTrials.gov registry record · Phase 3
Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 736
- Enrollment target
NCT02369874 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 736 participants.
The verdict
NCT02369874, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 736 participants
- Enrollment target
Study Summary
This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus SoC therapy in the target patient population.
Interventions
- DRUG Standard of Care
- DRUG MEDI4736
- DRUG MEDI4736 + Tremelimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 736 participants |
| Start Date | 2015-09-09 |
| Est. Completion | 2020-11-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02369874
The ClinicalTrials.gov registry entry for NCT02369874 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 736 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Standard of Care is the first listed.
NCT02369874 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02369874 about?
NCT02369874 is a clinical study titled "Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer". This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus SoC therapy in the target patient population.
What is the current status of trial NCT02369874?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 736 participants. The study started on 2015-09-09. Estimated completion is 2020-11-13.
What interventions are being tested in trial NCT02369874?
The interventions under investigation include: Standard of Care (DRUG), MEDI4736 (DRUG), MEDI4736 + Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT02369874?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.